JP7319348B2 - 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用 - Google Patents

二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用 Download PDF

Info

Publication number
JP7319348B2
JP7319348B2 JP2021502831A JP2021502831A JP7319348B2 JP 7319348 B2 JP7319348 B2 JP 7319348B2 JP 2021502831 A JP2021502831 A JP 2021502831A JP 2021502831 A JP2021502831 A JP 2021502831A JP 7319348 B2 JP7319348 B2 JP 7319348B2
Authority
JP
Japan
Prior art keywords
bcma
antibody
antigen
bispecific
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021502831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531005A (ja
JP2021531005A5 (enExample
Inventor
エリック・スミス
カラ・オルソン
フランク・デルフィーノ
デーヴィッド・ディリロ
ジェシカ・カーシュナー
オルガ・シネシュシェコワ
チィェン・ヂァン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67515169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7319348(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2021531005A publication Critical patent/JP2021531005A/ja
Publication of JP2021531005A5 publication Critical patent/JP2021531005A5/ja
Priority to JP2023117208A priority Critical patent/JP7586974B2/ja
Application granted granted Critical
Publication of JP7319348B2 publication Critical patent/JP7319348B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021502831A 2018-07-19 2019-07-18 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用 Active JP7319348B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023117208A JP7586974B2 (ja) 2018-07-19 2023-07-19 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862700596P 2018-07-19 2018-07-19
US62/700,596 2018-07-19
US201862750968P 2018-10-26 2018-10-26
US62/750,968 2018-10-26
US201962793645P 2019-01-17 2019-01-17
US62/793,645 2019-01-17
PCT/US2019/042447 WO2020018820A1 (en) 2018-07-19 2019-07-18 BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023117208A Division JP7586974B2 (ja) 2018-07-19 2023-07-19 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2021531005A JP2021531005A (ja) 2021-11-18
JP2021531005A5 JP2021531005A5 (enExample) 2022-07-25
JP7319348B2 true JP7319348B2 (ja) 2023-08-01

Family

ID=67515169

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021502831A Active JP7319348B2 (ja) 2018-07-19 2019-07-18 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用
JP2023117208A Active JP7586974B2 (ja) 2018-07-19 2023-07-19 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023117208A Active JP7586974B2 (ja) 2018-07-19 2023-07-19 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用

Country Status (34)

Country Link
US (3) US11384153B2 (enExample)
EP (2) EP3823664B1 (enExample)
JP (2) JP7319348B2 (enExample)
KR (1) KR20210034032A (enExample)
CN (1) CN112423785B (enExample)
AU (1) AU2019307928B2 (enExample)
BR (1) BR112021000186A2 (enExample)
CL (1) CL2021000131A1 (enExample)
CO (1) CO2021000188A2 (enExample)
CY (2) CY1127721T1 (enExample)
DK (1) DK3823664T3 (enExample)
ES (1) ES3010285T3 (enExample)
FI (2) FI3823664T3 (enExample)
FR (1) FR25C1029I2 (enExample)
HR (1) HRP20250199T1 (enExample)
HU (2) HUE070224T2 (enExample)
IL (1) IL279974B2 (enExample)
LT (2) LT3823664T (enExample)
MA (1) MA53168B1 (enExample)
MD (1) MD3823664T2 (enExample)
MX (2) MX2021000488A (enExample)
MY (1) MY201816A (enExample)
NL (1) NL301335I2 (enExample)
NO (1) NO2025036I1 (enExample)
PH (1) PH12021550031A1 (enExample)
PL (1) PL3823664T3 (enExample)
PT (1) PT3823664T (enExample)
RS (1) RS66535B1 (enExample)
SG (1) SG11202100252SA (enExample)
SI (1) SI3823664T1 (enExample)
SM (1) SMT202500044T1 (enExample)
TW (1) TWI838389B (enExample)
WO (1) WO2020018820A1 (enExample)
ZA (1) ZA202100087B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190320633A1 (en) 2016-11-30 2019-10-24 The Jackson Laboratory Humanized mouse model with improved human innate immune cell development
KR102745676B1 (ko) 2016-12-21 2024-12-24 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
CA3063588A1 (en) 2017-06-01 2018-12-06 Regeneron Pharmaceuticals, Inc. Human antibodies to bet v 1 and methods of use thereof
MX2021000532A (es) 2018-07-19 2021-04-12 Regeneron Pharma Receptores antigénicos quiméricos con especificidad para bcma y usos de estos.
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
SG11202109002XA (en) * 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
SI3819007T1 (sl) 2019-11-11 2024-10-30 Amgen Inc. Režim odmerjanja sredstev proti BCMA
CN114929343B (zh) * 2019-12-06 2025-03-18 瑞泽恩制药公司 用双特异性抗BCMA x抗CD3抗体治疗多发性骨髓瘤的方法
TW202144425A (zh) * 2020-04-17 2021-12-01 大陸商上海翰森生物醫藥科技有限公司 特異性抗原結合分子，其製備方法及醫藥用途
WO2022002033A1 (zh) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 具有H2L2与HCAb结构的结合蛋白
CA3177918A1 (en) 2020-07-01 2022-01-06 Amanda ATANASIO Methods of treating allergy using anti-bet v 1 antibodies
CN116194105A (zh) * 2020-09-14 2023-05-30 辉瑞大药厂 治疗癌症的方法、疗法及用途
WO2022060901A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
EP4214234A1 (en) 2020-09-18 2023-07-26 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof
CN118878694A (zh) * 2020-11-23 2024-11-01 康诺亚生物医药科技（成都）有限公司 一种双特异性抗体及其用途
CN114573703A (zh) * 2020-12-02 2022-06-03 康诺亚生物医药科技（成都）有限公司 一种t细胞衔接器治疗剂的开发和应用
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
TW202246333A (zh) * 2021-01-20 2022-12-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｂｃｍａ和ｃｄ３的抗原結合分子及其醫藥用途
RS66868B1 (sr) 2021-01-28 2025-06-30 Regeneron Pharma Kompozicije i postupci za lečenje sindroma oslobađanja citokina
CN115724996B (zh) * 2021-08-30 2026-03-20 上海君赛生物股份有限公司 含有膜表面结构域的多肽及其用途
CN118696058A (zh) 2021-12-03 2024-09-24 山东先声生物制药有限公司 抗bcma纳米抗体及其应用
CN118647724A (zh) * 2021-12-22 2024-09-13 杰克逊实验室 人源化小鼠模型
CA3247475A1 (en) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR THE DESTRUCTION OF UNIVERSAL TUMOR CELLS
CN117003871A (zh) 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 结合bcma和cd3的抗体及其用途
CN119546644A (zh) 2022-05-18 2025-02-28 瑞泽恩制药公司 结合cd38和4-1bb的多特异性抗原结合分子及其用途
KR20250021313A (ko) 2022-06-06 2025-02-12 산둥심시어 바이오파마슈티칼 씨오., 엘티디. Bcma, gprc5d 및 t 세포를 표적으로 하는 다중특이적 항체 및 그 응용
AR129560A1 (es) 2022-06-08 2024-09-04 Tidal Therapeutics Inc Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos
CN115368466A (zh) * 2022-07-19 2022-11-22 合肥天港免疫药物有限公司 双特异性抗体及其应用
CN120282798A (zh) 2022-10-10 2025-07-08 瑞泽恩制药公司 用于降低需要实体器官移植的受试者中的同种抗体水平的方法
CN117186230B (zh) * 2022-12-06 2024-04-16 成都赛恩吉诺生物科技有限公司 包含亲水性氨基酸的抗人bcma纳米抗体的双特异性抗体及应用
JP2026506095A (ja) 2023-02-17 2026-02-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃｄ３／ｔａａ二重特異性抗体に応答する誘導ｎｋ細胞
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN121335930A (zh) 2023-06-06 2026-01-13 信达生物制药(苏州)有限公司 抗gprc5d/bcma/cd3三特异性抗体的制备及其用途
TW202517293A (zh) 2023-07-07 2025-05-01 美商再生元醫藥公司 含有抗bcmax抗cd3雙特異性抗體之穩定化配製物
WO2025059362A1 (en) 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
IL327045A (en) 2023-10-05 2026-05-01 Capstan Therapeutics Inc Structure-restricted ionizable cationic lipids and lipid nanoparticles
WO2025131075A1 (zh) * 2023-12-21 2025-06-26 上海君实生物医药科技股份有限公司 抗cd3和抗cd3多特异性抗体及用途
US20250242018A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
TW202543581A (zh) 2024-02-12 2025-11-16 美商艾伊拉醫療公司 遞送組成物
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
TW202543585A (zh) 2024-03-08 2025-11-16 美商健臻公司 脂質奈米粒子
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025240287A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Methods of treating light chain amyloidosis with bispecific bcma x cd3 antibodies
WO2025244973A1 (en) 2024-05-20 2025-11-27 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bispecific bcma x cd3 antibodies
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof
WO2026015729A1 (en) 2024-07-11 2026-01-15 Regeneron Pharmaceuticals, Inc. Gprc5d x cd28 bispecific antibodies and methods of use thereof
WO2026059919A1 (en) 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bcma inhibitors in combination with cd38 inhibitors
WO2026059923A1 (en) 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bcma inhibitors in combination with an immunomodulator
WO2026059920A1 (en) 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bcma inhibitors in combination with pd1/pd-l1 inhibitors
WO2026059917A1 (en) 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bcma inhibitors in combination with proteasome inhibitors
WO2026059921A1 (en) 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bcma inhibitors in combination with lag3 inhibitors
WO2026072557A2 (en) 2024-09-24 2026-04-02 Genzyme Corporation Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies
WO2026072709A1 (en) 2024-09-25 2026-04-02 Orna Therapeutics, Inc. Chimeric antigen receptors targeting bcma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014047231A1 (en) 2012-09-21 2014-03-27 Regeneron Pharmaceuticals, Inc. Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
WO2017031104A1 (en) 2015-08-17 2017-02-23 Janssen Pharmaceutica Nv Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof
WO2018067331A1 (en) 2016-09-23 2018-04-12 Regeneron Pharmaceuticals, Inc. Bi specific anti-muc16-cd3 antibodies and nti-muc16 drug conjugates

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL211786B1 (pl) 1999-08-17 2012-06-29 Apoxis Sa Zastosowanie przeciwciała oraz polipeptydu
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
DE10206325A1 (de) 2002-02-14 2003-09-04 Medinnova Ges Med Innovationen Ummantelter Mikroorganismus
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
KR101589785B1 (ko) 2009-03-10 2016-01-28 바이오젠 엠에이 인코포레이티드 항-ｂｃｍａ 항체
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
HRP20151188T4 (hr) 2010-02-08 2021-10-01 Regeneron Pharmaceuticals, Inc. Miš sa zajedničkim lakim lancem
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
US20130273055A1 (en) 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
TWI638833B (zh) 2010-11-30 2018-10-21 中外製藥股份有限公司 細胞傷害誘導治療劑
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
SI3415531T1 (sl) 2011-05-27 2023-12-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) - vezni proteini
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
ES3065694T3 (en) 2012-04-11 2026-05-07 Us Health Chimeric antigen receptors targeting b-cell maturation antigen
ES2937015T3 (es) 2012-11-01 2023-03-23 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Anticuerpo contra CD269 (BCMA)
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US9963513B2 (en) 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
US20180112384A1 (en) 2013-12-30 2018-04-26 Craig Rothleitner Drainage treatment system
KR102526945B1 (ko) 2014-04-30 2023-04-27 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Ｃｄ269에 대한 인간화 항체
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
EP2982692A1 (en) * 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
BR112017010513A2 (pt) 2014-11-20 2018-04-03 F. Hoffmann-La Roche Ag ?cadeias leves comuns e métodos de uso?
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
EP3872094A3 (en) 2014-12-05 2021-12-08 Memorial Sloan Kettering Cancer Center Antibodies targeting b-cell maturation antigen and methods of use
SG11201704549UA (en) 2014-12-05 2017-07-28 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
EP3971210A1 (en) 2014-12-12 2022-03-23 2seventy bio, Inc. Composition for use in the treatment of b cell related conditions in a subject in need thereof comprisine an effector cell comrising a bcma chimeric antigen receptors
TWI700298B (zh) 2015-04-13 2020-08-01 美商輝瑞股份有限公司 靶向ｂ細胞成熟抗原之嵌合型抗原受體類
IL310723A (en) 2015-04-13 2024-04-01 Pfizer Therapeutic antibodies and their uses
CA2985816A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
KR102777500B1 (ko) * 2015-09-23 2025-03-11 리제너론 파아마슈티컬스, 인크. 최적화된 항-cd3 이중특이적 항체 및 이의 용도
AU2016353067B2 (en) 2015-11-13 2023-10-05 Sanford Research Anti-BCMA polypeptides and proteins
US20190256608A1 (en) 2015-12-01 2019-08-22 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
JOP20170017B1 (ar) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
SG11201805770UA (en) 2016-02-03 2018-08-30 Amgen Res Munich Gmbh BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
IL311107A (en) 2016-02-17 2024-04-01 Seagen Inc BCMA antibodies and their use for the treatment of cancer and immune disorders
US10689450B2 (en) 2016-04-01 2020-06-23 Kite Pharma, Inc BCMA binding molecules and methods of use thereof
US12048718B2 (en) 2016-06-07 2024-07-30 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
WO2018009904A2 (en) 2016-07-08 2018-01-11 Tumeh Paul C Compositions and treatment methods for cancer immunotherapy
MY200988A (en) 2016-09-14 2024-01-27 Teneobio Inc CD3 Binding Antibodies
WO2018075359A1 (en) 2016-10-18 2018-04-26 Boger Henry William Wireless power transfer for process control
EP3535295A1 (en) * 2016-11-02 2019-09-11 EngMab Sàrl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
WO2018099539A1 (en) 2016-11-29 2018-06-07 Horst Lindhofer Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
KR102745676B1 (ko) 2016-12-21 2024-12-24 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
JP7280828B2 (ja) 2017-01-23 2023-05-24 クレージュ メディカル カンパニー，リミテッド Ｂｃｍａを標的とする抗体およびその使用
CA3049689A1 (en) 2017-02-06 2018-08-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for augmenting antibody mediated receptor signaling
JP2020507605A (ja) 2017-02-17 2020-03-12 フレッド ハッチンソン キャンサー リサーチ センター Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
KR102700015B1 (ko) 2017-05-05 2024-08-29 암젠 인크 개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물
IL312322B2 (en) 2017-06-20 2026-05-01 Teneobio Inc Antibodies against BCMA containing only heavy chains
SG11202000499RA (en) 2017-08-01 2020-02-27 Medimmune Llc Bcma monoclonal antibody-drug conjugate
US11447559B2 (en) 2017-09-29 2022-09-20 Mogam Institute For Biomedical Research Anti-BCMA antibody having high affinity for BCMA and pharmaceutical composition for treatment of cancer, comprising same
SI3694529T1 (sl) 2017-10-13 2024-10-30 Harpoon Therapeutics, Inc. Trispecifične beljakovine in načini uporabe
CN107827989A (zh) 2017-10-18 2018-03-23 银丰生物工程集团有限公司 靶向骨髓瘤bcma抗原的转基因t细胞及其制备方法与应用
CN110709425B (zh) 2018-02-01 2022-09-16 南京驯鹿医疗技术有限公司 一种结合bcma的嵌合抗原受体（car）及其应用
CN112912397B (zh) * 2018-05-24 2025-03-14 詹森生物科技公司 抗cd3抗体及其用途
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
SG11202109002XA (en) * 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014047231A1 (en) 2012-09-21 2014-03-27 Regeneron Pharmaceuticals, Inc. Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
WO2017031104A1 (en) 2015-08-17 2017-02-23 Janssen Pharmaceutica Nv Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof
WO2018067331A1 (en) 2016-09-23 2018-04-12 Regeneron Pharmaceuticals, Inc. Bi specific anti-muc16-cd3 antibodies and nti-muc16 drug conjugates

Also Published As

Publication number Publication date
SI3823664T1 (sl) 2025-03-31
EP4516810A3 (en) 2025-07-16
EP3823664B1 (en) 2025-01-08
MX2021000488A (es) 2021-04-12
TW202019966A (zh) 2020-06-01
US12258412B2 (en) 2025-03-25
FIC20253006I1 (fi) 2025-08-14
LT3823664T (lt) 2025-02-25
HRP20250199T1 (hr) 2025-04-11
CN112423785B (zh) 2025-03-04
BR112021000186A2 (pt) 2021-08-10
ES3010285T3 (en) 2025-04-02
EP4516810A2 (en) 2025-03-05
MA53168B1 (fr) 2025-03-28
AU2019307928B2 (en) 2025-09-25
TWI838389B (zh) 2024-04-11
FR25C1029I1 (fr) 2025-09-26
FR25C1029I2 (fr) 2026-03-27
NO2025036I1 (no) 2025-08-07
SMT202500044T1 (it) 2025-03-12
US20260008862A1 (en) 2026-01-08
JP2023134728A (ja) 2023-09-27
IL279974B1 (en) 2025-03-01
CA3107126A1 (en) 2020-01-23
MX2025005515A (es) 2025-06-02
HUE070224T2 (hu) 2025-05-28
HUS2500032I1 (hu) 2025-09-28
PT3823664T (pt) 2025-01-24
PH12021550031A1 (en) 2021-09-20
NL301335I2 (nl) 2025-09-10
PL3823664T3 (pl) 2025-03-17
MD3823664T2 (ro) 2025-06-30
DK3823664T3 (da) 2025-02-17
CN112423785A (zh) 2021-02-26
CY2025020I2 (el) 2026-02-25
MA53168A (fr) 2021-05-26
CO2021000188A2 (es) 2021-01-18
LTPA2025526I1 (enExample) 2025-07-25
IL279974A (en) 2021-03-01
JP2021531005A (ja) 2021-11-18
US20200024356A1 (en) 2020-01-23
AU2019307928A1 (en) 2021-02-11
ZA202100087B (en) 2025-07-30
RS66535B1 (sr) 2025-03-31
JP7586974B2 (ja) 2024-11-19
CY2025020I1 (el) 2026-02-25
SG11202100252SA (en) 2021-02-25
MY201816A (en) 2024-03-19
US11384153B2 (en) 2022-07-12
CL2021000131A1 (es) 2021-07-02
CY1127721T1 (el) 2026-02-25
EP3823664A1 (en) 2021-05-26
KR20210034032A (ko) 2021-03-29
IL279974B2 (en) 2025-07-01
US20220306758A1 (en) 2022-09-29
FI3823664T3 (fi) 2025-03-04
WO2020018820A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
JP7586974B2 (ja) 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用
US11919965B2 (en) Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies
US11905332B2 (en) Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof
KR20250011926A (ko) Cd38 및 4-1bb에 결합하는 다중특이적 항원 결합 분자, 및 이의 용도
CA3107126C (en) Bispecific anti-bcma x anti-cd3 antibodies and uses thereof
HK40122455A (en) Bispecific anti-bcma x anti-cd3 antibodies and uses thereof
OA21950A (en) Multispecific antigen binding molecules that bind CD38 and 4-1BB, and uses thereof.
HK40052527A (en) Bispecific anti-bcma x anti-cd3 antibodies and uses thereof
HK40052527B (en) Bispecific anti-bcma x anti-cd3 antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220714

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230620

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230720

R150 Certificate of patent or registration of utility model

Ref document number: 7319348

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150